| scholarly article | Q13442814 |
| P50 | author | William W Busse | Q57330018 |
| Stanley J Szefler | Q65559413 | ||
| P2093 | author name string | Andrew H Liu | |
| Michelle A Gill | |||
| Christine A Sorkness | |||
| Wayne J Morgan | |||
| George T O'Connor | |||
| Agustin Calatroni | |||
| Peter J Gergen | |||
| Meyer Kattan | |||
| Jacqueline A Pongracic | |||
| Herman E Mitchell | |||
| Jeremy J Wildfire | |||
| Kristie Ross | |||
| Stephen J Teach | |||
| P2860 | cites work | The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update | Q37441960 |
| Results of a home-based environmental intervention among urban children with asthma | Q39694109 | ||
| Inner City Asthma Study: relationships among sensitivity, allergen exposure, and asthma morbidity | Q39709992 | ||
| Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). | Q43694602 | ||
| Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma | Q43701894 | ||
| The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics | Q43723871 | ||
| Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. | Q53310678 | ||
| The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects | Q73442941 | ||
| Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma | Q84893829 | ||
| Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial | Q24655820 | ||
| Pest and allergen exposure and abatement in inner-city asthma: a work group report of the American Academy of Allergy, Asthma & Immunology Indoor Allergy/Air Pollution Committee | Q28395141 | ||
| The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma | Q29615637 | ||
| Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma | Q34312701 | ||
| Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy | Q34412092 | ||
| Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children | Q34979344 | ||
| Allergen-specific IgE as a biomarker of exposure plus sensitization in inner-city adolescents with asthma | Q35936386 | ||
| Dealing with heterogeneity of treatment effects: is the literature up to the challenge? | Q37253011 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacodynamics | Q725307 |
| teenager | Q1492760 | ||
| inner city | Q1739536 | ||
| P304 | page(s) | 163-171 | |
| P577 | publication date | 2013-02-26 | |
| P1433 | published in | The Journal of Allergy and Clinical Immunology: In Practice | Q24056070 |
| P1476 | title | Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents | |
| P478 | volume | 1 |
| Q99346264 | Advances in understanding and reducing the burden of severe asthma in children |
| Q47551081 | Anti-IL5 therapies for asthma. |
| Q50120034 | Anti-IgE and Biologic Approaches for the Treatment of Asthma |
| Q38900049 | Asthma Management for Children: Risk Identification and Prevention |
| Q26782718 | Biomarkers and severe asthma: a critical appraisal |
| Q99630533 | Case Report: Acute effect of benralizumab on asthma exacerbation without concomitant corticosteroid use |
| Q101564338 | Defining pediatric asthma: phenotypes to endotypes and beyond |
| Q38616563 | Emerging monoclonal antibodies as targeted innovative therapeutic approaches to asthma. |
| Q38742430 | Epigenetics and allergy: from basic mechanisms to clinical applications. |
| Q90406910 | Measuring Airway Inflammation in Asthmatic Children |
| Q24186306 | Mepolizumab versus placebo for asthma |
| Q38574776 | Omalizumab therapy for children and adolescents with severe allergic asthma. |
| Q47745562 | Patient-reported outcomes in moderate-to-severe allergic asthmatics treated with omalizumab: a systematic literature review of randomized controlled trials |
| Q28073074 | Personalized Medicine in Allergy |
| Q47914370 | Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study |
| Q36373455 | Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations |
| Q39633151 | Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria. |
| Q38843261 | The path to personalized medicine in asthma. |
| Q37062124 | Treatment of moderate to severe pediatric asthma: Omalizumab and potential future use of monoclonal antibodies |
| Q35322784 | Type 2 inflammation in asthma--present in most, absent in many |
Search more.